ONCONETIX, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1171 USD | +0.69% |
|
-1.60% | -40.86% |
| 04-11 | Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-13 | Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors | CI |
| Sales 2022 | - | Sales 2023 | 0.06 4.66 | Capitalization | 3.64M 290M |
|---|---|---|---|---|---|
| Net income 2022 | -13M -1.04B | Net income 2023 | -37M -2.95B | EV / Sales 2022 | - |
| Net cash position 2022 | 25.75M 2.05B | Net Debt 2023 | 5.33M 425M | EV / Sales 2023 | 153,458,137 x |
| P/E ratio 2022 |
-1
x | P/E ratio 2023 |
-0.09
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.63% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.69% | ||
| 1 week | -1.60% | ||
| 1 month | -23.96% | ||
| 3 months | -38.72% | ||
| 6 months | -69.97% | ||
| Current year | -40.86% |
1 week
0.11
0.13
1 month
0.100.25
Current year
0.100.46
1 year
0.101.58
3 years
0.1090.90
5 years
0.1090.90
10 years
0.1090.90
| Managers | Title | Age | Since |
|---|---|---|---|
Ralph Schiess
CEO | Chief Executive Officer | 46 | 12-14 |
Bruce Harmon
DFI | Director of Finance/CFO | 66 | 30/09/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Meier
BRD | Director/Board Member | 62 | 02-05 |
Ajit Singh
BRD | Director/Board Member | 60 | 02-06 |
James Sapirstein
CHM | Chairman | 63 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 0.1156 | -1.28% | 213,520 |
| 30/04/24 | 0.1171 | +0.69% | 36,196 |
| 29/04/24 | 0.1163 | -0.17% | 316,341 |
| 26/04/24 | 0.1165 | -3.24% | 159,244 |
| 25/04/24 | 0.1204 | -1.39% | 89,834 |
End-of-day quote Nasdaq, April 29, 2024
More quotes
Onconetix Inc., formerly Blue Water Biotech Inc., is a commercial stage biotechnology company. The Company is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company has Entadfi, a Food and Drug Administration (FDA) approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patientâs risk of having clinically significant prostate cancer.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -40.86% | 2.61M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.48% | 31.28B | |
| +57.86% | 25.27B | |
| -13.58% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- ONCO Stock
